During the pandemic, were great vaccines bad business? A company-by-company review Matthew Herper By Matthew Herper March 25, 2024

https://www.statnews.com/2024/03/25/covid-vaccine-financial-winners-losers-pfizer-biontech-moderna-astrazeneca/?utm_campaign=morning_rounds&utm_medium=email&_hsmi=299647194&_hsenc=p2ANqtz--1vtCcy0V1_jzyGIvzIcuX0c-U6NFaKeEkrosHCgGBI5g_5-i5QsieJDsO2IdlBdUbQFMGOGo_gS-PdSRo6ugMR_mkkg&utm_content=299647194&utm_source=hs_email It’s been four years since Covid-19 emerged and I began to spend every day pacing the long hallway of my railroad apartment in Queens. A key factor in taming a pandemic that killed millions of people and brought the world to its knees was the creation of effective vaccines, which have saved millions of lives. You might assume developing these shots was an unmitigated financial win for companies. And, indeed, for Pfizer and its partner BioNTech, as well as for Moderna, the revenues generated were absolutely staggering. But investors have shrugged those sales off as gains that will not be repeated. STAT’s Matthew Herper offers an in-depth assessment of how each major pharmaceutical company fared in the vaccine race. Read more to see the real winners, the winning losers, the biggest loser, and more.